Journal SINTA 1
Review Article and Clinical Experience METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)
Folia Medica Indonesiana · Vol. 41 No. 1 (2005)
- ISSN
- 2355-8393, 2599-056X
- Published
- 2005-01-01
- Publisher
- Airlangga University
- Language
- en
Abstract
Metabolic Syndrome = MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002), respectively. Both AACE and ACE stated that insulin resistance plays central role in the syndrome. All these terms of the syndrome are originally and firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in 1999. Either MS or DMS or IRS has become major issues because of its impact on the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The criteria of MS, IRS (including its risk factors), and the clusters of components belong to MS and IRS, are listed in this paper. Rational strategies for the treatment of MS and IRS are focused on obesity and insulin resistance, respectively, and can be summarized as follows A. Improving insulin sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4 times/week). B. Pharmacological Interventions directed to the targets for (mmHg, ml/dl) Blood Pressure 40 for men, and > 50 for women. Clinical evidence-based data supported, that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of MS/IRS. However, the drugs specifically to improve the insulin sensitivity are hoped to treat this Syndrome. Conclusions Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become major issues because of their roles in the development of either T2DM or Cardiovascular Diseases. The cluster of components of this Syndrome and its risk factors should be well recognized. Improving insulin sensitivity, losing body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin, Orlistat) are rational strategies for the treatment of MS/IRS.
Keywords
Collaboration network of the authors
8 authors · 16 co-authorship links · 7 across different organisations
Hover or tap a name to highlight its co-authors. Double-click to open the author's page.
- Universitas Airlangga
- University of Brawijaya
- Rumah Sakit Umum Pusat Dr. Sardjito
- Affiliation unknown
- Different organisations
- Same organisation
- Affiliation unknown
- Thicker line = more joint articles · bigger circle = more articles
Show as table
| Co-author | Organisation | Joint articles |
|---|---|---|
| Agung Sindu Pranoto | Universitas Airlangga | 1 |
| Hermina Novida | Universitas Airlangga | 1 |
| Jongky Hendro Prayitno | Affiliation unknown | 1 |
| Adeodatus Yuda Handaya | Rumah Sakit Umum Pusat Dr. Sardjito | 1 |
| Djanggan Sargowo | University of Brawijaya | 1 |
| Diana Lyrawati | University of Brawijaya | 1 |
| Mohammad Aris Widodo | University of Brawijaya | 1 |
Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.